Journal article
Glucose-Insulin-Potassium Therapy in Patients With ST-Segment Elevation Myocardial Infarction
Abstract
CONTEXT: The clinical benefit of glucose-insulin-potassium (GIK) infusion in patients with ST-segment elevation myocardial infarction (STEMI) is unclear. While some smaller trials suggest benefit, in the CREATE-ECLA trial, GIK infusion had no effect on 30-day mortality in 20,201 patients.
OBJECTIVES: To determine the association between GIK infusion therapy and 30-day and 6-month outcomes in patients with STEMI.
Authors
Díaz R; Goyal A; Mehta SR; Afzal R; Xavier D; Pais P; Chrolavicius S; Zhu J; Kazmi K; Liu L
Journal
JAMA: The Journal of the American Medical Association, Vol. 298, No. 20, pp. 2399–2405
Publisher
American Medical Association (AMA)
Publication Date
November 28, 2007
DOI
10.1001/jama.298.20.2399
ISSN
0098-7484